
Browsing restrictions can be lifted for a fee.
Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, manufactures and sells various pharmaceutical products in Taiwan. The company offers products in the areas of medical beauty, kidney, respiratory tract, gastrointestinal tract, and body and hair cleaning. It also provides oral drugs and topical preparations; hand and mechanical disinfection, body lotion, and skin disinfection products; and pet health products, including surgical and skin prescriptions. Panion & Bf Biotech Inc. was founded in 1976 and is headquartered in Taipei, Taiwan.
1760
寶齡富錦
-2.49%
(-0.02)
The most recent financial report for 寶齡富錦 (1760) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1760's short-term business performance and financial health. For the latest updates on 1760's earnings releases, visit this page regularly.
According to historical valuation range analysis, 寶齡富錦 (1760)'s current price-to-earnings (P/E) ratio is 21.98, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 寶齡富錦 (1760) reported an Operating Profit of 99.52M with an Operating Margin of 18.71% this period, representing a growth of 71.51% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 寶齡富錦 (1760) announced revenue of 531.95M, with a Year-Over-Year growth rate of 6.13%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 寶齡富錦 (1760) held Total Cash and Cash Equivalents of 379.98M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 寶齡富錦 (1760) achieved the “three margins increasing” benchmark, with a gross margin of 56.45%%, operating margin of 18.71%%, and net margin of 14.17%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1760's profit trajectory and future growth potential.
According to the past four quarterly reports, 寶齡富錦 (1760)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.88. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
寶齡富錦 (1760)'s Free Cash Flow (FCF) for the period is 31.57M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 914.88% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.